.
There is an unmet need for efficacious, low-risk therapies against NASH and NASH-to-HCC transition. Although several drugs (e.g., those decreasing blood sugar levels) are in phase 2 and 3 
in 6-month ND-fed or CD-HFD-fed mice; arrows indicate platelets (n = 7 mice/group). Scale bar, 50 µm. b, 3D confocal images of platelet (green)/liver endothelium (gray) interaction of 6-month ND-fed or CD-HFD-fed mice (n = 4 mice/group). Scale bar, 20 μm. c,d, CD42b staining and quantification in 6-month (c) ND-fed and WD-HTF-fed (n = 6 mice/group) or (d) WD-NTF-fed mice; arrows indicate platelets, (ND n = 12 mice; WD-HTF n = 4 mice). Scale bars, 50 µm. e, CD42b staining and quantification of intrahepatic platelets (CD42b + ) in 2-month ND-fed or MCD-fed mice; arrows indicate platelets (n = 5 mice/group). Scale bar, 50 µm. f, CD61 staining and quantification of platelets (CD61 + ) in human livers; arrows indicate platelets (nondiseased patients n = 4; patients with NASH n = 21). g, H&E staining, CD42b staining and quantification in 6-month ND-fed or HFD-45%-fed mice (ND n = 6 mice; HFD-45% n = 7 mice). Scale bar, 50 µm. h, H&E, CD42b staining and quantification in 6-month ND-fed or HFD-60%-fed (60% kcal and low sucrose (LS)) mice (ND n = 8 mice; HFD n = 6 mice). Scale bar, 50 µm. All data are shown as mean ± s.e.m. All data were analyzed using two-tailed Student's t test.
Results

Hepatic accumulation of activated platelets in NASH.
To test whether platelets contribute to NASH development, we investigated platelet number and distribution in livers of C57Bl/6 mice fed a choline-deficient, high-fat diet (CD-HFD). Platelet numbers (Fig. 1a) and aggregate size (Fig. 1b) were significantly increased compared with those of age-matched normal chow diet (ND)-fed controls (Fig. 1a) , whereas platelet counts in peripheral blood remained normal ( Supplementary Fig. 1a ). Although fibrinogen levels and prothrombin time (PT) remained unchanged, activated partial thromboplastin time (aPTT) was significantly reduced ( Supplementary  Fig. 1a ). Ex vivo analyses of circulating platelets revealed no significant differences in activation or aggregation responses in CD-HFDfed mice compared with ND-fed mice ( Supplementary Fig. 1b ). We next analyzed other dietary and genetic murine NASH models (Fig. 1c-e and Supplementary Fig. 1c,d ), including high-fat, highfructose, high-cholesterol, 'Western-style' diets 24, 25 with or without trans fat (WD-HTF; WD-NTF); a 'Western-style' diet with fructose (WD-FSDW) 26 ; a methionine-and choline-deficient diet (MCD) and an inducible knock-in mouse expressing the human unconventional prefoldin RPB5 interactor (URI) in hepatocytes (hURI-tetOFFhep) 27 . All models induced NASH with varying NAFLD Activity Score (NAS) and degrees of fibrosis ( Supplementary Fig. 2a,b) , a primary determinant of outcome in NASH 28, 29 , and displayed a significant increase in intrahepatic platelet numbers compared to controls (Fig. 1a ,c-e; Supplementary Fig. 1c,d ). Further, human NAFLD/NASH patients displayed a significant increase in intrahepatic platelets in liver compared to healthy controls ( Fig. 1f ; Supplementary Table 1) .
In contrast, mice fed a 45% kcal high-fat diet (HFD), displaying only steatosis, or mice fed a 60% kcal HFD with low sucrose (HFD-60% + LS) experiencing only simple steatosis and insulin resistance 30 , lacked any significant increase in intrahepatic platelet numbers, despite increased body weight, NAS, liver damage and insulin resistance (Fig. 1g,h and Supplementary Fig. 3a-c) . Intrahepatic platelet activation in NASH was confirmed by electron microscopy (EM) (Supplementary Fig. 3d ). Thus, increased intrahepatic platelet number, platelet aggregation and platelet activation were specific to NASH.
Asp-Clo treatment is an APT currently used in several diseases (e.g., coronary stent thrombosis) 31 . We first addressed whether CD-HFD-fed mice would respond to APT. Compared with untreated CD-HFD-fed mice, Asp-Clo-treated mice displayed significantly lower intrahepatic platelet numbers ( Supplementary  Fig. 4a-c) , as well as reduced platelet aggregation and activation ( Supplementary Fig. 4d ). To investigate the effects of APT on human NAFLD, we performed a pilot case study (German Clinical Trials Register (DRKS) 587/2016BO2) with patients at risk for NAFLD (body mass index >30 and/or diabetes mellitus type II) undergoing a heart catheter procedure. Depending on the outcome of the catheter procedure, one of three approaches was carried out: (1) patients received dual antiplatelet therapy (DAPT) for at least 6 months if a coronary stent was implanted; (2) ASA monotherapy was given for at least 6 months if coronary artery disease (CAD) was present but stent implantation was not indicated; (3) no anti-aggregation therapy was given if coronary artery disease was absent. None of the patients included received long-term treatment with ASA or P2Y12 before study inclusion ( Supplementary Fig. 5a and Supplementary Table 2 ). In this pilot case study of 24 individual patients/observations, platelet function analyses revealed that patients generally responded well to APT ( Supplementary  Fig. 5b ), although serum total cholesterol, LDL and HDL cholesterol remained unchanged ( Supplementary Fig. 5b ,c). For control, we investigated patients without APT (Supplementary Table 2 ). Patients with NAFLD underwent liver MRI, liver ultrasound and serum analysis at study inclusion and after 6 months of follow-up. APT-treated patients with NAFLD showed significantly reduced liver volume and liver fat mass ( Supplementary Fig. 5d-f) . Patients who received a new therapy with ASA or DAPT were diagnosed with CAD. The standard treatment in patients with CAD includes statins. Therefore, patients who received a new anti-aggregation therapy were usually treated with a new statin treatment if statins were not already administered on a regular basis and if contraindications were absent. Thus, statins might present a significant confounder in the actual pilot case study, which we tried to address by performing a linear regression analysis. Because the study collective was small, we included age, gender, anti-aggregation and new statin treatment in the regression analysis. For the course of liver fat, we found the strongest associations for anti-aggregation (b = −0.334, 95% CI −4.719, 1.197, P = 0.226), whereas initiation of a new statin treatment showed weaker associations (b = −0.095, 95% CI −3.551, 2.526, P = 0.726). For the course of liver volume, we found associations for anti-aggregation (b = −0,454, 95% CI -0.170, 0.006, P = 0.066) that were stronger compared with . Statistic: ND vs CD-HFD (black asterisks), ND vs CD-HFD/Asp-Clo (green asterisks). b, ALT of 6-and 12-month ND-, CD-HFD or CD-HFD/Asp-Clo-fed mice (6 months: ND n = 14 mice; CD-HFD n = 11 mice; CD-HFD/Asp-Clo n = 4 mice; 12 months: ND n = 7 mice; CD-HFD n = 12 mice; CD-HFD/Asp-Clo n = 18 mice). c, Intraperitoneal glucose tolerance test (IPGTT) of 6-month ND-, CD-HFD-or CD-HFD/Asp-Clo-fed mice (n = 5 mice/group). Statistic: ND vs CD-HFD (black asterisks), ND vs CD-HFD/Asp-Clo (green asterisks). d,e, Liver triglyceride (6 months: ND n = 11 mice; CD-HFD n = 15 mice; CD-HFD/Asp-Clo n = 7 mice; 12 months: ND n = 4 mice; CD-HFD n = 9 mice; CD-HFD/Asp-Clo n = 15 mice) (d) and serum cholesterol (e) of 6-and 12-month ND-, CD-HFD-or CD-HFD/Asp-Clo-fed mice (6 months: ND n = 4 mice; CD-HFD n = 7 mice; CD-HFD/Asp-Clo n = 9 mice; 12 months: ND n = 6 mice; CD-HFD n = 17 mice; CD-HFD/Asp-Clo n = 11 mice). f, Real-time qPCR analysis for genes involved in lipid metabolism/β-oxidation of 6-month ND-, CD-HFD-or CD-HFD/Asp-Clo-fed mice (ND n = 4 mice; CD-HFD n = 5 mice; CD-HFD/Asp-Clo n = 7 mice). Statistic: CD-HFD vs CD-HFD/Asp-Clo (green asterisks). g, Analysis of VO 2 and respiratory exchange ratio (RER) over time in 2-month ND-, CD-HFD-or CD-HFD/Asp-Clo-fed mice (ND n = 4 mice; CD-HFD n = 8 mice; CD-HFD/Asp-Clo n = 8 mice). h, Analysis of food (g/mouse/day) and water intake (ml/mouse/day) (ND n = 4 mice; CD-HFD n = 8 mice; CD-HFD/Asp-Clo n = 6 mice). i, MRI analyses in 6-month ND-, CD-HFD-or CD-HFD/Asp-Clo-fed mice (n = 3 mice/group). T1 (fast low-angle shot (FLASH)) OUT phase: dark color indicative of steatosis. T2 TurboRare: an increase in subcutaneous and abdominal fat and hepatic lipid accumulation (bright regions). j,k, H&E staining (j) and NAS evaluation (k) of 6-month ND-, CD-HFD-or CD-HFD/Asp-Clo-fed mice (ND n = 9 mice; CD-HFD n = 9 mice; CD-HFD/Asp-Clo n = 6 mice). Asterisks indicate damaged hepatocytes. Scale bars, 100 µm in 10×, 50 µm in 20×. All data are shown as mean ± s.e.m. Data in a and c were analyzed by two-way analysis of variance (ANOVA) with the post hoc Tukey's multiple comparison test; *P < 0.05.,**P < 0.01, ***P < 0.001, ****P < 0.0001. Data in b, d, e, g, h and k were analyzed by one-way analysis of variance with the post hoc Tukey's multiple comparison test. Data in f were analyzed by two-tailed Mann-Whitney test; *P < 0.05, **P < 0.01.
Articles
NATurE MEDICINE
initiation of a new statin treatment (b = 0.047, 95% CI -0.084, 0.101, P = 0.847). This finding indicated that effects of anti-aggregation were stronger than those of statin administration. Notably, n = 4 patients showed significant reductions in liver fat content and/or liver volume without new statin therapy. However, there was a trend toward effect of anti-aggregation without being statistically significant. Higher body mass index did not significantly affect liver fat or liver volume.
Asp-Clo treatment attenuates NASH and NASH-associated conditions. We next investigated whether Asp-Clo (adjusted to the body weight) affects NASH or HCC development in mice receiving ND, CD-HFD or CD-HFD with Asp-Clo for 12 months. Weight gain over time was significantly higher in CD-HFD and CD-HFD/Asp-Clo-fed mice compared with ND-fed controls (Fig. 2a) . Similar to body weight, epididymal fat (eWAT) weight in CD-HFD/Asp-Clo-fed mice was not different from that in Scale bar, 43 μm. All data are shown as mean ± s.e.m. All data were analyzed using two-tailed Student's t test.
A c a d 1 0 A c a t 3 A c a t 2 A c o t 2 A c s b g 1
A c o x 3 A c s l 1 C p t 1 G p a t P p a r δ A b c a 1 E l H L L i p e L p l M v d S q l e A c
Articles
NATurE MEDICINE
CD-HFD-fed mice ( Supplementary Fig. 6a ). Low platelet numbers were found in eWAT and remained unaltered ( Supplementary  Fig. 6b ). CD3 + T cell infiltration was significantly reduced by AspClo ( Supplementary Fig. 6c ). RNA-seq analysis of eWAT from NDand CD-HFD-fed mice revealed a different gene expression pattern resulting in spatial separation in the principal component analysis plot. Analysis of the most differentially expressed genes between diets showed upregulation of pathways involved in immune signaling, cell-cell interactions and extracellular matrix regulation in eWAT from CD-HFD-fed mice. In contrast, eWAT of CD-HFD-fed mice showed a significant downregulation in pathways involved in metabolism and antioxidant response (Supplementary Fig. 6d) . ALT, AST, liver/body weight ratio, platelet numbers and aggregation state were significantly lower in livers of mice fed CD-HFD/ Asp-Clo for 6 and 12 months (Fig. 2b, Supplementary Fig. 4a−d , Supplementary Fig. 7a,b) . Asp-Clo significantly improved glucose tolerance (Fig. 2c) , reduced liver triglycerides (Fig. 2d) and attenuated serum total cholesterol, LDL and HDL cholesterol ( Fig. 2e and Supplementary Fig. 7c,d ). Several genes involved in fatty acid β-oxidation, lipolysis and cholesterol metabolism are dysregulated during NASH development 11 . Asp-Clo treatment prevented downregulation of genes from all three groups (Fig. 2f) . CD-HFD/Asp-Clo-fed mice lacked statistically significant changes in oxygen consumption, respiratory exchange ratio (RER), physical activity or in food and water intake compared with CD-HFD-fed mice (Fig. 2g,h and Supplementary Fig. 7e ). These data were corroborated in WD-HTF-fed mice ( Supplementary Fig. 7f,g ).
To analyze platelet activation, P-selectin, a marker of α-granule release, and integrin αIIbβ3 activation were analyzed by means of flow cytometry. In Asp-Clo-treated CD-HFD-fed mice, circulating platelets showed markedly reduced integrin αIIbβ3 activation and P-selectin exposure compared with platelets in ND-fed and CD-HFD-fed mice in response to all tested agonists ( Supplementary  Fig. 8a ), suggesting that Asp-Clo treatment effectively reduced platelet activation. Levels of major platelet surface glycoproteins were unchanged ( Supplementary Fig. 8b ).
MRI analysis revealed subcutaneous/abdominal fat accumulation in CD-HFD-fed and CD-HFD/Asp-Clo-treated mice, but not in ND-fed controls (Fig. 2i) . However, liver steatosis was strongly ameliorated by Asp-Clo treatment in CD-HFD-fed mice (Fig. 2i) . Immune cell infiltration was reduced in 6-month CD-HFD/Asp-Clo-treated mice (Fig. 3a) . Flow cytometry analysis showed strong reduction in total number, effector differentiation (CD8 
/CD8
+ and NKT cells (Fig. 3b,c) . B cells remained unchanged in 6-month ND-, CD-HFD-or CD-HFD/Asp-Clo-fed mice ( Supplementary Fig. 9a,b) .
Analyses of several potentially carcinogenic inflammatory signaling pathways activated under CD-HFD were dampened by Asp-Clo ( Fig. 3d and Supplementary Fig. 9c ). Asp-Clo significantly reduced CD11b+F4/80
hi Kupffer cells in livers of WD-HTF-fed mice ( Supplementary Fig. 10a-d ). An unbiased t-distributed stochastic neighbor embedding (t-SNE)-based clustering approach identified nine myeloid sub-clusters ( Supplementary Fig. 11a ,b and Supplementary Fig. 11a-d ). This finding indicates that Asp-Clo influences the Kupffer cell compartment. Taken together, these data suggest that Asp-Clo treatment attenuated Kupffer cell activation, alongside reduced inflammatory myeloid cell infiltration in the injured liver. Altogether, Asp-Clo prevented NASH, reduced intrahepatic immune cell influx and dampened pathways potentially supporting hepatocarcinogenesis 32 . Next, we studied the effects of Asp-Clo treatment on CD-HFDinduced HCC 11 . Thirteen of 51 CD-HFD livers (~25%) displayed macroscopically visible tumors by 12 months (Fig. 3e-g ). In contrast, were analyzed by one-way ANOVA with the post hoc Tukey's multiple comparison test. Data in i were analyzed using two-tailed Student's t test. Data in j were analyzed using two-way analysis of variance with the post hoc Tukey's multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
CD-HFD/Asp-Clo-treated mice lacked macro-and microscopically visible liver tumors ( Fig. 3e-g and Supplementary Fig. 12a ). CD-HFD-fed mice treated with a lower dose of Asp-Clo (according to the initial body weight and not further adjusted to diet or age-related weight gain) developed significantly fewer HCC (3/52) compared with untreated CD-HFD-fed mice (13/51) ( Supplementary Fig. 12b ).
Therefore, continuously adjusting the dose of Asp-Clo to body weight is critical to fully prevent HCC. Articles NATurE MEDICINE livers revealed a significant induction in gene expression profiles involved in platelet activation, aggregation and degranulation (Extended Data Fig. 1a-i) . Moreover, NASH-related enrichment of genes was associated with expression of TNF superfamily members, cytokine and chemokine production and chemotaxis 11, 27 (Extended Data Fig. 1a-i ). Asp-Clo treatment significantly attenuated the latter, some of which are also released from activated platelets (e.g., CCL5, TGFβ) 33 ( Supplementary Fig. 13a ). Coupling high-resolution confocal microscopy and 3D reconstruction of liver sinusoids enabled visualization and quantification of platelet interactions with the liver endothelium and immune cells. Asp-Clo reduced NASH-related increase of platelet interaction with the liver endothelium, T cells and innate immune cells ( Supplementary Fig. 13b-f and 14a,b) .
Asp
To exclude COX2-dependent effects of Asp-Clo, we used another NSAID/COX1/2 inhibitor, sulindac. CD-HFD/sulindac-treated mice exhibit obesity; no significant changes in liver/body weight ratio, hepatic triglycerides and glucose tolerance; no significant alteration in gene expression involved in metabolism; severe steatosis; and increased liver damage comparable to that of CD-HFD-fed mice (Extended Data Fig. 2a-f ). Thus, Asp/Clo-mediated effects on NASH are COX independent.
To corroborate our results with another platelet inhibitor, CD-HFD-fed mice were treated with ticagrelor (CD-HFD/ticagrelor), an FDA-approved direct and reversible antagonist of the platelet P2Y12 receptor 34 for coronary artery disease used in the clinic (e.g., with ASA after coronary stent implantation in patients presenting with an acute coronary syndrome without increased bleeding risk) 35 . Intrahepatic platelet number, platelet/liver endothelium coverage, platelet aggregation, liver damage, liver triglycerides and serum cholesterol were significantly reduced in ticagrelor-treated mice, whereas very-low-density lipoprotein secretion was not affected (Extended Data Fig. 3a-h ). Expression of genes involved in cholesterol metabolism, 'de novo' lipogenesis and lipid storage were unchanged by the treatment, whereas downregulation of several genes involved in fatty acid oxidation and lipolysis that occurs in CD-HFD-fed mice (Extended Data Fig. 3i ,j) and in histopathological features of NASH were prevented by ticagrelor ( Supplementary Fig. 15a-c Fig. 15d ,e). In contrast to liver tissues, increased expression of genes involved in inflammation and fibrosis was found in eWAT from CD-HFD-and WD-HTF-fed mice receiving Asp-Clo or ticagrelor ( Supplementary Fig. 15f ). This finding indicates that APT is beneficial specifically to the liver, affecting intrahepatic platelets and immune cell infiltration and improving hepatic steatosis by maintaining normal expression of genes involved in lipid catabolism.
We next investigated whether ticagrelor would affect NASH-to-HCC transition. Compared with that in untreated CD-HFD-fed mice, ticagrelor treatment significantly reduced HCC development. One tumor was detected in 29 livers of CD-HFD/ticagrelor-treated mice ( Supplementary Fig. 16a ). The therapeutic potential of ticagrelor was tested in CD-HFD-fed mice with fully established NASH (4-month CD-HFD), followed by 8 weeks of ticagrelor treatment with CD-HFD. Intrahepatic platelet numbers, NAS and liver damage were reduced, but no difference in glucose tolerance was found ( Supplementary Fig. 17a ,b), and no effect on the blood immune cell populations was observed ( Supplementary Fig. 17c ). Similar results were obtained with therapeutic ticagrelor treatment in the context of a WD-HTF and of fibrosis; no difference in whole-body metabolism was found upon ticagrelor treatment in CD-HFD or WD-HTF mice (Supplementary Figs. 17d,e and 18a,b).
Early platelet recruitment in fatty liver correlates with liver damage, hepatocyte swelling and reduced sinusoidal diameter. To understand the dynamics of intrahepatic platelet recruitment and attachment during the initial events of NAFL preceding NASH, we performed intravital microscopy in CD-HFD or WD-HTFfed mice over 4, 5, 6 and 8 weeks post diet induction ( Fig. 4a and Supplementary Fig. 19a -c). Platelets were the first non-resident cell type to populate the liver at ≤4 weeks post diet induction in both CD-HFD-and WD-HTF-fed mice ( Articles NATurE MEDICINE Fig. 19a-c) . Platelets progressively aggregated and increased in number in liver sinusoids over 8 weeks in the absence of significantly elevated CD3 + T cells or Ly6G + granulocytes (Fig. 4a-d and Supplementary Fig. 19a-c) . Even at this early stage, mild steatosis, reduced sinusoidal diameter and hepatocyte swelling were observed (Fig. 4e,f and Supplementary Fig. 19e ). NAS and liver triglycerides were increased in CD-HFD-and WD-HTF-fed mice (Fig. 4g,h and Supplementary Fig. 19d-f ). Platelets interacted primarily with Kupffer cells, as determined by 3D high-resolution reconstruction (Fig. 4i) . Although intrahepatic granulocyte numbers remained unaltered in the first 8 weeks post diet induction, granulocytes might still support intrahepatic platelet recruitment and NAFL and NASH induction. Administration of anti-Ly6G antibodies via osmotic pumps for 8 weeks to CD-HFD-fed mice did not reduce intrahepatic platelet numbers but successfully reduced granulocytes. Experiments revealed no significant role of granulocytes in the early development of NAFL and borderline NASH ( Supplementary Fig. 20a-e) . 
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We next screened for possible adhesion molecules and danger markers responsible for early platelet attachment and recruitment. We found progressive induction of the extracellular matrix component hyaluronan colocalizing with hepatocytes, Kupffer cells and, to a lesser degree, on liver sinusoidal endothelial cells (LSECs) (Fig. 4j) .
Kupffer cell-dependent platelet recruitment involving hyaluronan-CD44 binding supports early and advanced stages of NAFL including NASH. To investigate the functional role of Kupffer cells and molecules involved in platelet-LSEC and platelet-immune cell interaction (e.g., hyaluronan, CD44) in borderline NASH, CD-HFD-or WD-HTF-fed mice were treated with clodronate liposomes (CLL), control liposomes (CL), hyaluronidase (HYAL), HYAL/CLL (double treatment), CD44-binding/HA-blocking AB (clone KM81) or CD44-binding/HA-non-blocking AB (clone IM7), for control ( Fig. 5a and Supplementary Fig. 21a,b) . Treatment with CLL and CLL/HYAL, but not CL reduced Kupffer cell numbers in CD-HFD-and WD-HTF-fed mice ( Fig. 5b and Supplementary  Fig. 21c,d ). CLL and HYAL reduced NAS significantly in CD-HFDand WD-HTF-fed mice ( Fig. 5b and Supplementary Fig. 21d ). CLL and HYAL treatments significantly reduced intrahepatic platelets (Fig. 5c) ; a significant reduction in liver damage was found following HYAL but not CLL (Fig. 5d ). Combined treatment with both CLL and HYAL did not result in a further decrease of platelet numbers ( Supplementary Fig. 21f,g ). Similar data (platelet reduction and NAS reduction) with CLL treatment were obtained using WD-HTFfed mice, although ALT levels remained elevated ( Supplementary  Fig. 21d,e) . Also, treatment with a CD44-binding/HA-blocking, but not with a CD44-binding/HA non-blocking antibody led to a reduction in NAS and liver damage (Fig. 5e-g ).
Notably, significantly reduced NAS, platelet accumulation, triglycerides, and liver damage by CLL treatment in mice fed CD-HFD for 6 months demonstrate a potential therapeutic effect of CLL even in a short treatment scheme (Fig. 5h,i and Supplementary  Fig. 22 ). These data imply that Kupffer cells, hyaluronan and CD44 are important players in the early and advanced stages of NAFL, including NASH.
Platelet cargo is indispensable for NASH development. Platelets release bioactive factors from intracellular granules in response to cellular activation. During thrombo-inflammatory reactions, the mostly proteinous components of α-granules are essential for immune cell recruitment and tissue damage 36 . Nbeal2-knockout mice (Nbeal2 -/-), which lack α-granules in platelets and are thus protected from thrombosis and thrombo-inflammatory tissue damage [37] [38] [39] were on a CD-HFD for 6 months. CD-HFD-fed Nbeal2
mice displayed no significant difference in intrahepatic platelet number or aggregation and gained weight similarly to CD-HFDfed controls ( Fig. 5j and Supplementary Fig. 23a ). Still, significantly lower serum ALT and AST levels were found in CD-HFD-fed Nbeal2 −/− mice compared with those in CD-HFD-fed mice (Fig. 5k) . This finding was paralleled by a significant decrease in liver triglycerides, lower serum cholesterol (Fig. 5l,m) , and improved glucose tolerance in CD-HFD-fed Nbeal2 −/− mice ( Supplementary Fig. 23b ). Deregulation of lipid metabolism genes found in CD-HFD livers was partially prevented in CD-HFD-fed Nbeal2 −/− mice ( Supplementary Fig. 23c ). CD-HFD Nbeal2 −/− livers lacked steatosis and NASH and displayed a lower NAS (Fig. 5n and Supplementary Fig. 23d ). Suppression of NASH in Nbeal2 −/− mice on CD-HFD was corroborated by significant diminution of lipid content (Fig. 5o) . Decreased T cell infiltration, neutrophil accumulation and macrophage activation were found in Nbeal2 −/− mice on CD-HFD (Supplementary Fig. 23e ). Together, these results indicated that platelet α-granule components contribute to NASH.
CD-HFD-induced NASH could not be rescued in mice lacking the GPIIb subunit of the platelet fibrinogen receptor GPIIb/IIIa (integrin α2β3; Itga2b −/− mice) which harbors activatable platelets unable to aggregate (Extended Data Fig. 4 ). This is in agreement with a recent study indicating that deletion of the platelet integrin α2β3 binding motif of fibrinogen did not alter NASH ) all developed NASH and NASH-associated conditions upon CD-HFD feeding (Extended Data Figs. 5-6) .
Mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) was recently discovered as an important player in NASH 42 . Animals with genetic depletion of MAdCAM-1 presented lower NAS and less liver damage after 6-month of WD-HTF 42 .
We analyzed livers of WD-HTF-fed mice lacking MAdCAM-1
) and both L-selectin and integrin beta7 (L-sel/β7
mice displayed significantly reduced intrahepatic platelet numbers correlating with a partial protection from NASH (Extended Data  Fig. 7a,b) . In contrast, deletion of MAdCAM-1 ligands integrin beta7, L-selectin and L-selectin/integrin beta7 did not affect intrahepatic platelet numbers or platelet aggregation and did not prevent, or only partially prevented, NASH (Extended Data Fig. 7a, b) .
Platelet GPIbα and α-granules are required to induce NASH.
Our data demonstrate that intrahepatic interaction of platelets with Kupffer cells, involving hyaluronan/CD44 binding and platelet cargo function, but not platelet aggregation contribute to NASH. Platelet-derived GPIbα has been implicated in platelet attachment and activation 43 We thus hypothesized that GPIbα might mediate early platelettrafficking/activation in NASH livers 43 . We first analyzed the interaction of GPIbα with parenchymal and non-parenchymal liver cells (LSECs; Kupffer cells, etc.) in NASH. 3D reconstruction revealed that the most abundant interactions of GPIbα + platelets were with Kupffer cells and less so with LSECs in mouse and human NASH samples ( Fig. 6a,b; Supplementary Fig. 24a) .
Thus, we blocked the major ligand binding domain of GPIbα in 6-month CD-HFD-fed mice therapeutically using antigen-binding fragments (Fab) of the anti-GPIbα antibody pop/B 44 for 5 weeks. Notably, this short therapeutic treatment significantly reduced intrahepatic platelet accumulation in the presence of CD-HFD (Fig. 6c,d) . Consequently, steatosis, NAS, liver damage, liver triglycerides and intrahepatic immune cell infiltration were reduced; fibrosis was dampened (Fig. 6c-h and Supplementary Fig. 24b-d) . Additionally, anti-GPIbα antibody treatment reduced intrahepatic protein expression of several pro-inflammatory and homeostatic cytokines and chemokines, including CCL5, CCL6, ICAM-1, P-selectin and CD40, linking intrahepatic platelet activation and Nbeal2-dependent cargo release with mediators of inflammation ( Supplementary Fig. 24e ).
We next tested whether therapeutic anti-GPIbα antibody treatment would prevent fatty liver-to-NASH transition in early disease progression (e.g., after 6-week CD-HFD; Fig. 4) . However, these treatments did not ameliorate NAFL/ borderline NASH, most likely due to lack or low expression of yet unidentified GPIbα ligands at early disease stages ( Supplementary Fig. 24f,g ). These data highlight distinct mechanisms of platelet recruitment in early versus established NAFL/borderline NASH-still involving Kupffer cells at both disease stages.
To corroborate the above data in a genetic model, we fed transgenic mice expressing an IL-4rα/GPIbα fusion-protein in a GPIbα -/-background 45 in which the ligand-binding ectodomain of GPIbα is replaced by the α-subunit of the human IL-4 receptor (hIL4rα/ GPIbα-Tg) 45 with a CD-HFD for 6 months. Remarkably, platelet aggregate size, platelet area and platelet-liver endothelium coverage were significantly lower in CD-HFD-fed hIL4Rα/GPIbα-Tg mice compared with those off CD-HFD-fed C57Bl/6 controls ( Supplementary Fig. 25a-c) . Both hIL4rα/GPIbα-Tg and C57Bl/6 mice gained weight similarly when fed a CD-HFD ( Supplementary  Fig. 25d ). Serum cholesterol, liver triglycerides, serum ALT and AST levels were significantly lower in CD-HFD/hIL4rα/GPIbα-Tg mice ( Fig. 6i,j; Supplementary Fig. 25e ), accompanied by less LDL and HDL cholesterol (Supplementary Fig. 25e) . Similarly, dysregulated mRNA expression of lipid metabolism-related genes in livers of CD-HFD-fed C57BL/6 mice was prevented in livers of CD-HFD/hIL4rα/GPIbα-Tg mice (Supplementary Fig. 25f ). We also observed strong and significant reductions in intrahepatic CD8
+ T and NKT cells by flow cytometry analysis (Fig. 6k) . Reduced CD3
+ and reduced macrophage influx and activation were observed using immunohistochemistry ( Supplementary Fig. 25g,h) . CD-HFD/hIL4rα/GPIbα-Tg mice showed lower intrahepatic protein expression of several pro-inflammatory and homeostatic cytokines and chemokines, including CCL5, CD40 and TNFRSF11B ( Supplementary Fig. 25i ), mechanistically linking platelet attachment and activation and cytokine and chemokine expression to efficient intrahepatic immune cell attraction. CD-HFD/hIL4rα/ GPIbα-Tg mice lacked histological features of NASH, paralleled by a reduction in lipid accumulation and absence of macrovesicular steatosis analyzed by H&E and Sudan red staining (Fig. 6l-o) .
Notably, mice lacking the major platelet adhesion receptors P-selectin (Selp , the known ligands of GPIbα, displayed full-blown NASH after 6 months of CD-HFD (Extended Data Figs. 8-10 ).
Finally, we investigated whether hIL4rα/GPIbα-Tg mice would develop HCC upon long-term CD-HFD. Of note, hIL4rα/GPIbα-Tg mice receiving CD-HFD for 12 months displayed significantly lower fibrosis and serum ALT, and lacked any macro-or microscopic evidence of HCC (Fig. 6p-u) .
Discussion
It is becoming increasingly clear that beyond their central role in hemostasis and wound repair after vascular injury 49 , platelets are key players in multiple pathophysiological conditions [16] [17] [18] 20 , including cytotoxic T lymphocyte-mediated liver damage and associated pathologies 18 . Here, we identified Kupffer cells as key players in intrahepatic platelet recruitment in early and advanced stages of NAFL, borderline NASH and NASH. In early NAFL and borderline NASH, hyaluronan and CD44 binding are also involved. In late NASH, GPIbα expressed by platelets appears to be primarily involved in the interaction of platelets with Kupffer cells and in the maintenance of NASH. Thus, Kupffer cells play distinct roles in intrahepatic platelet recruitment at different NAFLD stages.
We found no evidence for a role of platelet-derived GPIIb/IIIa (Itga2b -/-mice) in NASH, suggesting that platelet activation and adhesion are important, whereas platelet aggregation is dispensable.
What is the function of platelets recruited to the liver? Our results indicate a major contribution of the platelet cargo function (α-granule components) in NASH progression, exemplified by the marked protection of Nbeal2 -/-mice. The exact nature of plateletderived α-granule constituents is currently unclear. However, several chemokines and cytokines were reduced upon therapeutic anti-GPIbα antibody treatment in the liver, suggesting that the number and activation state of intrahepatic platelets directly or indirectly correlate with an increase in immune cell-attracting chemokines and cytokines.
The key role of GPIbα in NASH identified in this study parallels a similarly vital function of this receptor in the development of experimental autoimmune encephalomyelitis (EAE), where it orchestrates the recruitment of leukocytes to the inflamed CNS 50 . Our results, similar to those of the EAE study, argue against a key role of the three known cognate interaction partners of GPIbα: P-selectin, vWF and Mac-1 (refs. 48 , 51, 52 ) and point to a GPIbα-activation-dependent proinflammatory function of α-granules in intrahepatic immune cell attraction.
Selectins have also been shown to be dispensable for leukocyte recruitment in inflamed liver microvasculature 53 . Other interaction partners might be involved (e.g., coagulation factors XI, XII). It is also conceivable that GPIbα exerts its function in disease development independent of an ectopic ligand 54 . Moreover, due to the complex pathogenesis underlying NASH, it is plausible that GPIbα is not the only molecule involved. Mice lacking MAdCAM-1 (MAdCAM-1 -/-) also showed significantly reduced intrahepatic platelet infiltration, but the exact mechanisms by which this occurs is unknown.
Cholesterol also plays a pivotal role during NASH pathogenesis by inducing hepatic lipotoxicity 55 . Notably, different Western diets (e.g., HTF and NTF) with high cholesterol recapitulated plateletdependent phenotypes (increased intrahepatic platelets and responsiveness to therapeutic APT) described in the CD-HFD, but with a more pronounced NASH phenotype with higher NAS and fibrosis.
Of note, platelets and platelet-derived GPIbα are potential therapeutic targets of NASH and subsequent HCC development. Although GPIbα-antibody treatment induces prolonged bleeding time, it does not induce spontaneous bleeding 44 , as only one GPIbα epitope is blocked, leaving receptor function largely intact. Thus, GPIbα antibody is a potentially safe new treatment modality against a metabolic disease of major public health burden 4, 9 . So far, there is no drug treatment available specifically targeting NASH. The use of pioglitazone (most promising drug so far, off-label outside type II diabetes mellitus because of side effects) or vitamin E (better safety and tolerability in the short term) or combination thereof could be used for NASH treatment 4, 56 . Other agents such as obeticholic acid have also improved histological features of NASH, although data with respect to their long-term benefits are still awaited 57 . Combined therapies for NASH treatment are currently being pursued, as only a subset of patients respond well to monotherapies 5 . This might be overcome by stratifying more responsive patients to a given monotherapy or by utilizing multitarget drugs. A viable approach might be a metabolic target in combination with an anti-inflammatory or anti-fibrotic drug, such as APT and statins, as described in our pilot case study. Nevertheless, given that APT and anti-GPIbα treatment attenuated metabolic dysfunction, inflammation and fibrosis, these modalities constitute potential monotherapies against NASH. Although a risk for bleeding cannot be excluded for both, which warrants careful monitoring, a singlesubstance therapy is expected to harbor a lower risk of side effects compared with combined therapies.
Given that only a proportion of patients with NAFLD progress to NASH and HCC, the question remains at which stage of NAFLD such treatments should be initiated. Future studies are needed not only to identify novel druggable targets for NASH and HCC, but also to identify non-invasive biomarkers for detection of early NAFLD and NASH, when it is still amenable to therapeutic intervention. It was recently demonstrated that higher serum ALT correlated with HCC development not only in a mouse model of chronic liver cell damage, but also in patients with chronic liver disease of diverse etiology including NASH 11, 58 . Prophylactic APT, commonly used for acute and long-term treatment of coronary artery disease 59 , and ticagrelor attenuate NASH and NASH-induced HCC 16 . In contrast, sulindac did not prevent NASH in mice. Thus, rather than NSAIDs in general, therapies that specifically block intrahepatic platelet accumulation or platelet function seem to be required to prevent NASH and NASHassociated conditions.
For NASH, we also observed a therapeutic effect of APT in preventing NASH-triggered HCC (although potential therapeutic effects of APT in the context of pre-existing HCC was not tested) 60 . Similarly, we have observed a therapeutic anti-NASH effect of anti-GPIbα antibody treatment. Remarkably, in both cases, therapeutic treatment partially dampened fibrosis.
Furthermore, in a small prospective human cohort study, APT reduced liver volume and liver fat accumulation in patients with NAFLD, thus supporting the results of our murine in vivo experiments. The results of this pilot case study, being a starting point for further studies, have to be interpreted with caution as it is currently underpowered. Although a multivariate analysis on a small patient cohort inherently warrants careful interpretation, our data have shown that effects of anti-aggregation were stronger than those of statin administration.
In our study, NASH prevention (e.g., by two distinct APTs, ticagrelor and Asp/Clo, in hIL4rα/GP1bα-Tg mice) ultimately suppressed subsequent HCC formation, mostly because the pro-carcinogenic NASH-related environment (e.g., intrahepatic inflammation, signaling, hepatocyte damage) was lacking. Moreover, treatment with anti-GPIbα antibody or depletion of Kupffer cells abrogated NASH therapeutically. These approaches might have an important impact for chemo-preventive strategies, which are still lacking in NASH treatment. Thus, our findings provide a rationale for APT, P2Y12 antagonists or reagents directly blocking platelet-derived GPIbα or related pathways as possible therapeutic approaches for patients with NASH, not only to prevent or revert NASH but also to prevent NASH-to-HCC transition.
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Blood 87, 1238-1242 (1996 Five-week-old mice were fed ad libitum: a normal diet (ND) (Provimi Kliba) or a choline-deficient high-fat diet (CD-HFD) (Research Diets; D05010402) for 6 or 12 months; a Western diet with trans-fat (WD-HTF) (Research Diets; D09100301: 40 kcal % fat (Primex shortening), 20 kcal % fructose, 2% cholesterol) for 6 or 7.5 months; or a methionine-choline-deficient diet (MCD) (MP Biomedicals) for 4 weeks; and control mice were fed a calorifically matched control diet, a Western diet with fructose in drinking water (WD-FSDW) (Custom Research Diet TD.06303; Harlan Laboratories in conjunction with fructose-supplemented drinking water: 55% fructose, 45% glucose by weight at a concentration of 42 g/l) ad libitum for 6 and 9 months. Control animals received ND and nonsupplemented drinking water.
Cohorts of mice fed CD-HFD or WD-HTF were in addition treated with either aspirin (through food pellets containing 7.5 mg per kg of food) in combination with clopidrogel high (40 μg/ml drinking water; ~3 mg/kg/day) or low dose (20 μg/ ml drinking water; ~1.5 mg/kg/day), with sulindac (200 μg/ml drinking water; ~20 mg/kg/day) or with ticagrelor (40 μg/ ml drinking water; ~3 mg/kg/day).
For interventional studies 5-week-old male mice were fed a normal diet (ND), a choline-deficient high-fat diet (CD-HFD) (Research Diets; D05010402) or a Western diet containing trans-fat (WD-HTF) (Research Diets, D09100301) for 3.5 weeks and then treatment started for 2.5 weeks, twice per week intravenously in 100 µl PBS of either 20 µg/mouse anti-CD44 antibody (clone KM81, Cedarlane, CL8944AP), 100 µg/mouse anti-CD44 (clone IM7, Bioxcell, BE0039), 100 µl/ mouse Clodrosome (liposomal clodronate), 100 µl/mouse Encapsome (Control Liposomes), 100 µg/mouse anti-GPIbα or 100 µg/mouse Fab-Rat IgG (kindly provided by B.N., University Hospital and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany) or intraperitoneally 20 U/g murine hyaluronidase (HYAL). In late treatment regimes, mice were fed CD-HFD for 6 months and treated with the same protocol for indicated time points.
For the osmotic pump experiment, 5-week-old male mice were fed a cholinedeficient high-fat diet (CD-HFD) (Research Diets; D05010402) for 12 weeks. Four weeks after the diet, mini pumps (Alzet, model 2004) were implanted subcutaneously into the mice to deliver 30 μg per day of Ly6G (clone 1A8, Bioxcell, BP0075) neutrophil-depleting antibody or Rat IgG2a (clone 2A3, Bioxcell, BE0089) for 8 more weeks. At the end of the experiment, animals were culled, and the liver, fat and serum were harvested for analysis. The prospective clinical trial has been listed at the German Clinical Trials Register (DRKS), evaluated and accepted by the local ethical authorities (Ethik-Kommission Universitätsklinikum Tübingen) with the ID 587/2016BO2, under the name 'Platelet inhibition to recues formation of non-alcoholic steatohepatitis in cardiovascular patients' (Prometheus-prospective, monocenter, observational study).
Prospective trial, ethics, MRI and ultrasound analyses. The case study of 24 individual observations prospective trial was approved by the institutional ethics committee (587/2016BO2) and complies with the declaration of Helsinki and the good clinical practice guidelines [63] [64] [65] [66] . For the prospective, ongoing case study, we have included only patients (n = 23) with diabetes mellitus type II and/or body mass index >30, two risk factors, that are highly correlated with development of NAFLD or NASH. All patients underwent cardiac catheretization due to suspected coronary artery disease (CAD). Patients received no antiplatelet treatment if CAD was excluded. Patients received antiplatelet therapy with 100 mg acetylsalicylic acid (ASA) once daily if CAD was present but coronary stent implantation was not indicated. Patients received dual antiplatelet therapy with ASA 100 mg once daily and P2Y12 inhibitor (clopidogrel 75 mg once daily, ticagrelor 90 mg twice daily or prasugrel 10 mg once daily) depending on acuity and severity of CAD (e.g., myocardial infarction versus stable CAD). None of the patients included received long-term treatment with ASA or P2Y12 before study inclusion.
All patients remained on the respective treatment regimens until follow-up. All patients underwent liver MRI and liver ultrasound at baseline (within 4 weeks after hospital discharge) and after 6 months of follow-up. The serum from all patients was analyzed for classic liver damage parameters like AST, ALT, bilirubin, GGT, etc. Additional measurements were performed to exclude reasons other than NAFLD for liver damage, e.g., immune hepatitis, viral hepatitis and AFLD. All patients underwent the Michigan Alcoholism Screening Test to evaluate drinking habits. Patients with left ventricular ejection fraction <45% or severe valve diseases were not included in the study due to the risk of liver congestion.
The hepatic lipid accumulation was quantified by 3T MRI (Skyra, Siemens Healthcare, Erlangen, Germany) at the Department of Diagnostic and Interventional Radiology of the University Hospital of Tübingen, Germany. A commercially available multi-echo Dixon sequence (LiverLab, Siemens Healthcare, Erlangen, Germany) was used, allowing the computation of proton density fat fraction maps and inline segmentation of the liver. Ultrasound examinations in patients were performed twice, at the time of patient recruitment and 6 months after patient recruitment. In order to identify patients presenting with signs of liver steatosis or with signs of liver cirrhosis, bright hepatic echos, increased hepatorenal echogenicity, presence of nodular liver morphology and signs of portal hypertension (e.g., splenomegaly, ascites or intra-abdominal varices) were analyzed using an Aplio 500/T1 (Toshiba)/Ultrasonic transducer 3-5 MHz.
The multivariate analysis (age, gender, anti-aggregation and new statin treatment) to identify statin administration as a possible confounder of the observed effects, patients were differentiated into groups, that received statin treatment prior to hospital admission and those that received new statin treatment at hospital discharge prior to the first MRI examination. We performed a linear regression analysis.
For further details regarding the human samples, please refer to Supplementary Tables 1a,b and 2.
Cholesterol measurements. Hyperlipidemia is defined as baseline LDL cholesterol ≥160 mg/dl and triglycerides ≥200 mg/dl. Interestingly, only three of the patients of the prospective cohort had triglyceride values ≥200 mg/dl. However, all patients of the prospective cohort showed significantly elevated liver fat accumulation, indicating that patients might not need elevated serum lipid levels to develop fatty liver disease. According to our measurements, only three patients of the prospective trial fulfill the diagnosis hyperlipidemia. However, we decided to include patients with pre-existing conditions, e.g., diagnosis by family doctor, because serum lipid undergoes dynamic regulations. This explains the discrepancy between hyperlipidemia and measured lipid levels in baseline Table 2 .
Isolation of liver leukocytes for in-depth myeloid characterization. Livers were perfused once with PBS, then digested via collagenase at 37 °C for 40 minutes (collagenase type IV, Worthington, UK). Additionally, 0.1 mg/ml DNase I was added after 20 min. Single-cell suspension was obtained by filtering the digested liver through a 70-μm mesh. Hepatocytes were removed by low-speed centrifugation (50 r.c.f., 1 min), and density gradient centrifugation was performed using 18% Nycodenz dissolved in Gey's Balanced Salt Solution (GBSS) as previously described 67 . Cells were then stained for CD206 (C068C2, 141708), CX3CR1 (SA011F11, 149031), CD3 (17A2, 100218), MHCII (M5/114.15.2, 107632) (all BioLegend); CD11b (M1/70, 48-0112-82), F4/80 (BM8, 25-4801-82) (all Invitrogen); CD86 (GL-1, eBioscience, 12-0862-82); CD45 (30-F11, 557659), Ly6G (RB6-8C5, 566218), Ly6C (1A8, 562737) CD11c (HL3, 562949), CD31 (MEC13.3, 565097), NK1.1 (PK136, 557391), TIM-4 (RMT4-54, 564147) (all BD Bioscience), and then multicolor flow cytometry was run using an LSR Fortessa (BD Biosciences). Analysis was done using FlowLogic (v7.2, Inivai, Australia) and FlowJo (v10.
For details regarding the definitions of violin plot elements of Supplementary  Fig. 3i , refer to Supplementary Table 3 .
t-distributed stochastic neighbor embedding (t-SNE). Liver leukocytes were pregated for living (7-AAD-), CD45
+ , Ly6G -, CD31 -, F4/80 + cells by using FlowJo (v10.4, BD Biosciences), then t-SNE-based clustering was done as described previously 68 , using the Rtsne package for R. Clusters were identified by hierarchical clustering and projected onto the two-dimensional t-SNE plot, while relative protein expression was displayed for each cluster by violin plots using R (v3.5.1).
nCounter gene expression analysis. Gene expression analysis of 561 selected gene targets of liver MoMF and Kupffer cells was performed using NanoString assays (nCounter Mouse Immunology Kit, NanoString Technologies). Analysis was done using the nSolver Software (v2.0, NanoString Technologies). PCA was done using the prcomp package for R (v3.5.1).
Measurement of serum parameters. Serum was isolated from mice and liver enzymes AST and ALT were quantified using the Roche Modular System (Roche Diagnostics) with a commercially available automated colorimetric system at the Institute of Clinical Chemistry at the University Hospital Zurich using a Hitachi P-Modul (Roche). Total cholesterol was measured in a 96-well format using CHOL or TG GPO-PAP substrates (Roche Diagnostics).
Measurement of liver triglycerides. Liver-specific triglyceride levels were analyzed from snap frozen liver tissue samples. Liver tissue samples were homogenized in sodium chloride (0.9 % NaCl), and liver-resident lipids were precipitated using ethanolic potassium hydroxide (0.5 M KOH) and solubilized in magnesium sulphate (0.15 M MgSO 4 ). The concentration of hepatic triglycerides was then measured using triglycerides GPO-PAP from Roche Diagnostics on a spectrophotometer at 505 nm.
Intraperitoneal glucose tolerance test. Intraperitoneal glucose tolerance tests were carried out on mice fasted overnight for 16 h. Basal blood glucose concentrations were determined for each mouse prior to glucose (2 mg/g body weight) administration using a hand-held glucose analyzer (FreeStyle Freedom Lite; Abbott). Each mouse then received glucose via intraperitoneal injection, and blood glucose concentrations were subsequently remeasured 15, 30, 60 and 120 min post glucose administration.
Intraperitoneal insulin tolerance test and fasting insulin determination.
Intraperitoneal insulin tolerance tests were carried out on mice mild fasted for 6 h. Basal blood glucose concentrations were determined for each mouse prior to insulin (1U/g lean mass determined by EchoMRI analysis) administration using a hand-held glucose analyzer (FreeStyle Freedom Lite; Abbott). Each mouse then received Insulin via intraperitoneal injection and blood glucose concentrations were subsequently re-measured 15, 30, 60 and 120 min post glucose administration. Fasted insulin levels were measured in mildly fasted (8 h) mice using the ALPCO mouse insulin ELISA kit.
Immunoblot analysis. Liver homogenates were prepared in a pH 7.4 lysis buffer containing 1% NP-40 (Sigma-Aldrich, Gillingham, UK), 50 mmol/L Tris, 10% glycerol, 0.02% NaN3, 150 mmol/L NaCl, and a cocktail of phosphatase and protease inhibitors (Sigma-Aldrich), and protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo Scientific) according to the manufacturer's manual. Liver homogenates were prepared using a homogenizer. Tissue preparation was performed with gentleMACS Octo Dissociator (Miltenyi Biotec). 20-80 μg of proteins were separated under reducing conditions (2.5% β-mercaptoethanol) by gel electrophoresis (Mini Protean Gels, Bio Rad) and blotted by semi-dry blotting (Trans-Blot Turbo Transfer, Bio Rad) onto nitrocellulose membranes (Bio Rad). Membranes were blocked in 5% milk/ PBS-T for at least 1 h at RT. Primary antibodies against P-p38MAPK ((Thr180/ Tyr182) D3F9, 4511), p38 MAPK (D13E1, 8690), P-p65 (Ser536, 3033), p65 (D14E12, 8242), COX2 (D5H5, 12282), GAPDH (14C10, 2118) (all Cell Signaling) were incubated at 4 °C overnight under shaking conditions. Incubation with the secondary antibody (HRP-anti-rabbit IgG, 1:5000; Promega, W4011) was performed under shaking conditions for 1 h. Detection was achieved using Clarity Western ECL Substrate (Bio Rad) with the Stella 3200 imaging system (Raytech). Intracellular cytokine staining (ICS) was performed as described previously 11 . Peptides used for restimulation were 10 μg/ml of the relevant antigen: Trp2180-188 (SVYDFFVWL), Her2/Neu66-74 (TYVPANASL), Tyrp-1455-463native (TAPDNLGYA), or gp10025-33native (EGSRNQDWL). Cells were analyzed using BD FACS LSR II, BD FACS LSR Fortessa, BD FACSCanto, and Sony spectral analyzer SP6800 flow cytometers, and data were analyzed using FlowJo.
Histology, immunohistochemistry, scanning and automated analysis. Liver samples were fixed in 4% paraformaldehyde and paraffin-embedded at the University Hospital Zürich, Department of Pathology and Molecular Pathology Core, at the Technical University of Munich (TUM), or at the DKFZ, Department of Chronic Inflammation and Cancer (Heidelberg) as described 11 . Briefly, 2 μm sections from FFPE and cryo-preserved tissues were prepared and stained with Hematoxylin/Eosin or IHC antibodies. Incubation in Ventana buffer and staining was performed on a NEXES immunohistochemistry robot (Ventana Instruments) using an IVIEW DAB Detection Kit (Ventana) or on a Bond MAX (Leica). For Sudan Red staining, cryo sections (5 µm) were cut and stained with Sudan Red (0.25% Sudan IV in ethanolic solution). Slides were scanned with a Nano Zoomer (Hamamatsu, Japan).
Antibodies that were used included anti-MHCII, rat, 1:500 (clone M5/114.15.2, NBP1-43312); anti-CD3, rabbit, 1:250 (clone SP7, Abcam, ab16669); and anti-F4/80, rat, 1:50 (BioLegend, BM8, cat. no. 123105). Further antibodies used included collagen IV, rabbit 1:50 (Cedarlane, clone CL50451AP-1, 007CL50451AP); Ki67, rabbit 1:200 (Thermo Scientific, clone RM-9106-S1, RM-9106-S1); B220, rat 1:3000 (BD, clone RA3-6B2, 553084); Ly6G rat 1:600 (BD, clone 1A8, 551459), PERK1/2, rabbit, 1:400 (Cell Signaling, clone D13.14.4E, 4370); glutamine synthethase (GS) rabbit 1:500 (Abcam, ab16802); PSTAT3, rabbit, 1:100 (Cell Signaling clone D3A7, 9145); and CD42b, rabbit, 1:200 (Abcam, clone SP219, ab183345).
For quantification of stains, slides were scanned using a SCN400 slide scanner (Leica) and analyzed using Tissue IA image analysis software (4.0.6 Slidepath, Leica). For quantification of platelet staining on human (CD61) and mouse (CD42b) tissue, software-based analysis and counting at the screen (CD42b; 100 high-power fields; 40×) were performed.
For Sudan red + liver area, data are presented as Sudan red-positive area in percent of total tissue area. Three random liver tissue areas of approximately 6-8 mm² (87,000 µm 2 ) were selected in DIH (digital image hub, Leica), submitted to analysis and merged.
NAFLD activity score (NAS) was applied to murine livers.
Electron microcopy. For electron microscopy, sections from epon-embedded, glutaraldehyde-fixed liver samples were cut and stained with toluidine blue. The tissue was trimmed, and ultrathin cross sections of the liver were cut and treated with uranyl acetate and lead citrate as described previously 69 . Electron micrographs were analyzed for cell composition and localization using the analySIS Docu System (Soft Imaging System).
Preparation of mouse platelets. Blood was obtained from the tail of each mouse and drawn into citrate tubes at a 1:10 ratio. Platelet-rich plasma (PRP) was obtained by centrifugation at 260g for 5 min. Afterward, platelet-rich plasma was centrifuged at 640g for 5 min to pellet the platelets. After two washing steps, the pellet of washed platelets was resuspended in modified Tyrode-HEPES buffer (pH 7.4, supplemented with 1 mM CaCl 2 ).
Platelet aggregometry. Washed platelets were adjusted to a concentration of 150 × 10 3 platelets/µl in Tyrode-HEPES buffer (pH 7.4 supplemented with 1 mM CaCl 2 ). Aggregation was estimated from light transmission determined with a luminoaggregometer model 700 (ChronoLog, Havertown, PA, USA). Following calibration, agonists including adenosine 5′-diphosphate (ADP), U46619 (U46), thrombin (Thr), collagen-related peptide (CRP), rhododcytin (RC) were added at the indicated concentrations, and aggregation was measured for 10 min with a stir speed of 1,000 r.p.m. at 37 °C. Afterward, analysis was performed using the aggrolink8 software (ChronoLog).
Analysis of platelets and flow cytometry of platelets. Mice were bled under isoflurane anesthesia. Blood was collected in a tube containing 20 U/ml heparin, and PRP was obtained by two cycles of centrifugation at 300g for 6 min at room temperature. For preparation of washed platelets, PRP was washed twice at 800g for 5 min at RT, and the pellet was resuspended in modified Tyrodes-HEPES (N-2-hydroxyethyl-piperazone-N′2-ethanesulfonic acid) buffer (134 mM NaCl, 0.34 mM Na 2 HPO 4 , 2.9 mM KCl, 12 mM NaHCO 3 , 5 mM HEPES, 1 mM MgCl 2 , 5 mM glucose, 0.35% BSA, pH 7.4) in the presence of prostacyclin (0.1 μg/ml) and apyrase (0.02 U/ml).
Apyrase grade III (Sigma-Aldrich), prostacyclin (PGI2), ADP (Sigma-Aldrich), U-46619 (Enzo Life Sciences), thrombin (Roche), rabbit anti-human VWF (DAKO), rabbit anti-human fibrinogen (DAKO) were purchased as indicated. CRP and rhodocytin were generated and isolated as previously described 36 . The antibody against the activated form of integrin αIIbβ3 (JON/A-PE) was from Emfret Analytics. Other antibodies we received, listed below, were generated in the laboratory of B.N.
RNA isolation and quantitative real-time PCR. Total RNA was isolated from snap frozen liver tissues according to the manufacturer's protocol using RNeasy Mini Kit (Qiagen). The quantity and quality of the RNA were determined spectroscopically using a Nanodrop analyzer (Thermo Scientific). 1 μg of purified RNA was subsequently transcribed into cDNA using Quantitect Reverse Transcription Kit (Qiagen) according to the manufacturer's protocol. Quantitative RT-PCR was performed using Fast Start SYBR Green Master Rox (Roche). Primers were custom made by Microsynth as previously described 11 . For mRNA expression analysis, quantitative real-time PCR was performed in duplicates in 384-well plates using Fast Start SYBR Green Master Rox (Roche) on a 7900 HT qRT-PCR system (Applied Biosystems, Life Technologies Darmstadt, Germany). Relative mRNA levels were calculated according to the ΔΔC t relative quantification method and were normalized to levels of a housekeeping gene (GAPDH or ROTH2). The data were normalized to the expression of the housekeeping gene and analyzed using GraphPad Prism software version 7.03 (GraphPad Software). For the analysis of whole liver homogenates by microarray (Agilent), the following genes were selected, analyzed and shown. For a list of all used primers for RT-qPCRs, refer to Supplementary Table 4 .
Gene expression profiling. Transcriptional profiling was performed using SurePrint G3 Mouse Gene Expression 8 × 60 k microarrays (Agilent Technologies, AMADID 28005) according to the manufacturer's protocol. 75 ng of total RNA was used in labeling using the Low Input Quick Amp Labeling Kit (one-color, Agilent Technologies). Raw gene expression data were extracted as text files with the Feature Extraction software 11.0.1.1 (Agilent Technologies). The expression microarray data were uploaded to ArrayExpress (www.ebi.ac.uk/arrayexpress/), and the data set is available under the accession number E-MTAB-6073, entitled 'Transcriptomic differences in livers of mice fed with normal diet and cholinedeficient high-fat diet' .
All data analysis was conducted using the R statistical platform (version 3.2.2, www.r-project.org). Data quality assessment, filtering, preprocessing, normalization, batch correction based on nucleic acid labeling batches and data analyses were carried out with the Bioconductor R-packages limma, Agi4x44PreProcess and the ComBat function of the sva R-package. All quality control, filtering, preprocessing and normalization thresholds were set to the same values as suggested in Agi4x44PreProcess R-package user guide. Only HGNC annotated genes were used in the analysis. GSEA was conducted on calculated log 2 -expression values of all array probes using the 'GSEA Pre-ranked' function with default settings 76 . RNA sequencing. Library preparation for bulk 3′-sequencing of poly(A)-RNA was done as described previously 77 . Briefly, barcoded cDNA of each sample was generated with a Maxima RT polymerase (ThermoFisher) using oligo-dT primer containing barcodes, unique molecular identifiers (UMIs) and an adapter. 5′ ends of the cDNAs were extended by a template switch oligo (TSO); after pooling of all samples, fulllength cDNA was amplified with primers binding to the TSO-site and the adapter. cDNA was tagmented with the Nextera XT kit (Illumina) and 3′-end-fragments finally amplified using primers with Illumina P5 and P7 overhangs. In comparison to Parekh et al. 77 , the P5 and P7 sites were exchanged to allow sequencing of the cDNA in read1 and barcodes and UMIs in read2 to achieve a better cluster recognition. The library was sequenced on a NextSeq 500 (Illumina) with 75 cycles for the cDNA in read1 and 16 cycles for the barcodes and UMIs in read2.
RNA sequencing analysis. Gencode gene annotations version M18 and the mouse reference genome GRCm38.p6 were derived from the Gencode homepage (https:// www.gencodegenes.org/). Dropseq tools v1.12 (ref. 78 ) was used for mapping the raw sequencing data to the reference genome. The resulting UMI filtered countmatrix was imported into R v3.4.4. Prior differential expression analysis with DESeq2 1.18.1 (ref. 79 ), dispersion of the data was estimated with a parametric fit including the dietary status of the mice as explanatory variable in the model. The Wald test was used for determining differentially regulated genes between the high-fat and normal diet group and shrunken log 2 fold changes were calculated afterward, with setting the type argument of the lfcShrink function to 'normal' . A gene was determined to be differentially regulated if the absolute log 2 fold change was greater than 1 and the adjusted P value was below 0.05. Gene set enrichment analysis was conducted with EnrichR 80 within the Reactome database. Raw sequencing data are available under the accession number MTAB-7625.
MRI analysis for mice. Steatosis was analyzed in 6-month-old B6 mice fed with ND, CD-HFD or CD-HFD/Asp-Clop treated groups. A Pharmascan 7 T MRI (Bruker) with Paravision 5.1 software was used in FLASH scan mode without fat suppression using an echo-time of 2.2 ms for out-phase and 2.9 ms for in-phase based on previous reports 81, 82 .
Calorimetric TSE analysis. Mice were individually housed for indirect calorimetry in PhenoMaster (TSE systems). Mice were allowed to acclimate to the new environment for at least 2-3 d, then metabolic parameters were measured, such as food and water intake, O 2 consumption, CO 2 production, respiratory exchange ratio and total activity. All parameters were measured for at least 4 consecutive d with five measurement values every hour. Analysis of covariance (ANCOVA) was first conducted to ensure that body weight does not play a significant effect on the measured parameters.
Immunofluorescence microscopy of liver sections. To achieve rapid fixation after euthanasia, livers were fixed with paraformaldehyde-lysine-periodate (PLP) for 4-8 h, rehydrated in 30% sucrose solution for 48 h and snap frozen in OCT (Cell Path). Thick (5 μm) cryosections were obtained using a Leica Cryostat and the Cryojane tape transfer system (Leica Microsystems).
Generation of liver slices for confocal microscopy. The generation of the liver slices for microscopy was performed and adapted from a previously described protocol 83 . Briefly, livers were collected and processed as described above. OCTembedded frozen livers were iteratively sectioned using a cryostat. Samples were then reversed and the procedure was repeated on the opposite face of the liver until a 30-µm-thick slice of liver was obtained. OCT freezing medium covering the sample was removed, and slices were washed with PBS and blocked overnight at 4 °C in blocking solution (0.2% Triton/1%BSA/10% donkey serum/PBS). Liver slices were stained with rat anti-CD41, goat anti-CD105, rabbit anti-Col IV and rabbit anti-CD8 for 3 d in blocking solution, washed overnight in PBS and stained with DyLight488 donkey anti-rabbit IgG and DyLight549 or DyLight649 donkey anti-rat IgG. Stained slices were then washed in PBS and incubated overnight in FocusClear (CelExplorer Lab). For observation under the confocal microscope, liver slices were embedded in FocusClear and mounted on glass slides.
Immunofluorescence staining. Livers were perfused with PBS through inferior vena cava, harvested and fixed in 4% paraformaldehyde for 16 h, then dehydrated in 30% sucrose prior to embedding in OCT freezing media (Sakura). 25-μm sections were cut on a HM550 cryostat (ThermoFisher) and adhered to Superfrost Plus slides (Thermo Scientific). Sections were then permeabilized and blocked in PBS containing 0.3% Triton X-100 (Sigma-Aldrich) and 10% FBS, then stained in the same blocking buffer. The following primary antibodies were used for staining: rabbit anti-collagen IV (1:200 Abcam, 10808); CD41 PE (1:100 MWReg-30 BioLegend, 133906), rat anti-F4/80 APC (1:100 BM8 ThermoFisher, 17-4801-82), rabbit anti-CD3 (1:100 DAKO A0445229-2), B220 AF 647 (1:100 RA3-6B2 BioLegend, 103226), CD11b APC (1:100 M1/70 BioLegend, 101212). Stained slides were mounted with fluorescence mounting medium (DAKO), and images were acquired on an inverted Leica microscope (TCS STED CW SP5, Leica Microsystems) with a motorized stage for tiled imaging.
To minimize fluorophore spectral spillover, we used the Leica sequential laser excitation and detection modality. The bleed-through among sequential fluorophore emission was removed by applying simple compensation correction algorithms to the acquired images. The semiautomatic surface-rendering module in Imaris (Bitplane) was used to create 3D volumetric surface objects corresponding either to individual cells or to the liver sinusoids. Signal thresholds were determined using the Imaris Surface Creation module, which provides automatic threshold identification and value-based visual surface thresholding around the positively stained objects.
For the semi-quantitative analysis of platelet adhesion to liver sinusoids, high-resolution confocal x-y-z stacks of 30x-y sections (1,024 × 1,024 pixels) sampled with 0.5 μm z spacing were acquired to provide image volumes of 388 × 388 × 30 μm
3
. The confocal z stacks were imported into Imaris software (Bitplane), and platelets were reconstructed as 3D volumes by means of the semiautomatic surface-rendering module with a seed point diameter of 2.08 μm (the mean platelet diameter 84, 85 ). The split touching objects option of the module supports the separation of two or more objects that are identified as one, enabling the splitting of aggregates into single components. All analysis was performed at least on 12 random fields of view (FOV).
Confocal imaging analysis.
For platelet aggregate size analysis, the surface and volume of each single platelet aggregate (containing more than two single platelets)
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NATurE MEDICINE from at least 12 different FOV was automatically obtained from the surfacerendering module (imaris, Bitplane); The PLT/endothelium coverage was derived from the same FOV as percentage of the total sinusoidal surface (calculated in each FOV) covered by PLT.
For quantification of the immune cell-PLT interaction, the immune cells (CD3 + , CD11b + and B220 + ) adjacent and non-adjacent to PLT were manually counted in 12 FOV. The interaction was expressed as total number of adjacent cells as well as percentage of cells adjacent to PLT over the total number of cells.
The CD3 + cells/PLT interaction was further analyzed by calculating, for each cell, the contact surface area between them.
Multiplex ELISA. Cytokines and chemokines in whole liver of ND, CD-HFD and Asp-Clo-treated CD-HFD mice (12 months old) were evaluated using a laser bead technology-based Mouse Cytokine Array Chemokine Array 31-Plex (MD31) by Eve Tech (Eve Technologies, Calgary, AB, Canada).
Cytokine profiler. Cytokines and chemokines in whole liver of ND, CD-HFD/ctrl ab and CD-HFD/anti-GPIbα antibody mice (6 months old) or in CD-HFD and CD-HFD/hIL4Rα/GPIbα-Tg mice (12 months old) were assessed using the Mouse XL Cytokine Array Kit by R&D Systems.
Spinning-disc microscopy. All imaging experiments were performed using 7-to 12-week-old male mice. All mice were co-housed and bred in a specific-pathogenfree facility at the University of Calgary with a 12 h light/dark cycle and access to food and water ad libitum.
Preparation for intravital Microscopy. Multichannel spinning-disk confocal microscopy was used to image the liver as previously described (Surewaard and Kubes 2017). Briefly, mice were anesthetized by intraperitoneal injection of ketamine (200 mg/kg body weight; Bayer Animal Health) and xylazine (10 mg/ kg body weight; Bimeda-MTC). A catheter was inserted into the tail vein to allow administration of fluorescently conjugated antibodies, proteins and additional anesthetics. A midline and lateral abdominal incision were made, and the abdominal wall was partly removed to access the liver. The mouse was placed in a right lateral position on a heating plate to maintain body temperature at 37 °C. The liver was exteriorized onto a glass coverslip and covered with moisturized laboratory tissues to restrict movement and breathing artefacts. Abdominal organs were covered with saline-soaked gauze to prevent dehydration.
Intravital microscopy. Image acquisition of the liver was performed using an inverted spinning-disk confocal microscope (IX81; Olympus), equipped with a focus drive (Olympus) and a motorized stage (Applied Scientific Instrumentation). The microscope was fitted with a motorized objective turret equipped with 43/0.16 UPLANSAPO, 103/0.40 UPLANSAPO, and 203/0.70 UPLANSAPO objective lenses. The microscope was linked with a confocal light path (WaveFx; Quorum Technologies) based on a modified CSU-10 head (Yokogawa Electric Corporation). Cells of interest were visualized using fluorescently conjugated antibodies. Volocity software (Perkin Elmer) was used to drive the confocal microscope and for acquisition and analysis of images.
Antibodies for intravital imaging. Antibodies for intravital imaging were as follows: Alexa Fluor (AF) 750-conjugated anti-mouse F4/80 (2 μg/mouse; clone BM8; AbLab, custom made), Alexa Fluor (AF) 647-conjugated anti-mouse CD49b (3 μg/mouse; clone HMa2; BioLegend, 103511), PE-conjugated anti-mouse Ly6G (3 μg/mouse; clone 1A8; BioLegend, 127607) and FITC-conjugated anti-mouse CD3e (2 µg(mouse; clone 145-2c11; eBioscience, 11-0031-82). HAPB (SigmaAldrich) was fluorescently (Alexa Fluor 555; Invitrogen) conjugated and injected intravenously to detect intrahepatic HA.
In vivo treatments. Kupffer cell depletion was performed by intravenous injection of 100 µl Clodronate (17 mM) twice a week for 2 weeks. Hyaluronidase (SigmaAldrich) was given by intraperitoneal injection twice a week at a dose of 20U/g per mouse for 2 weeks. The last dose was given 3 h before intravital imaging.
Statistical analyses.
Mouse data are presented as the mean ± s.e.m. Pilot experiments and previously published results were used to estimate the sample size such that appropriate statistical tests could yield significant results. Statistical analysis was performed using GraphPad Prism software version 7.03 (GraphPad Software). Data of three or more groups were analyzed by analysis of variance with the post hoc Tukey's or Bonferroni multiple comparison test. Data for the three groups over time were analyzed by two-way analysis of variance with the post hoc Tukey's multiple comparison test. Analysis of two samples was performed with two-tailed Student's t test and the Mann-Whitney t test, and statistics for HCC incidence were calculated using two-tailed Fisher's exact test. Statistical significance is indicated either as exact P value or as follows:*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; 'n.s. ' indicates not significant.
Moreover, the data that support the findings of this study are available from the corresponding authors upon reasonable request. If not stated otherwise, the authors declare that all other data supporting the findings of this study are available within the paper and its supplementary information files. Fig. 6a and Supplementary Fig. 12 have associated source data that are uploaded to ArrayExpress (www.ebi.ac.uk/arrayexpress/) and the data set is available under the accession number E-MTAB-6073, entitled 'Transcriptomic differences in livers of mice fed with normal diet and choline-deficient high-fat diet' .
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Data that support the findings of this study have been uploaded to ArrayExpress (www.ebi.ac.uk/arrayexpress/) and the data set is available under the accession number E-MTAB-6073, entitled 'Transcriptomic differences in livers of mice fed with normal diet and choline-deficient high-fat diet' . 
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Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The datasets generated during and/or analysed during the current study are available in the [ArrayExpress] repository, (www.ebi.ac.uk/arrayexpress/); under the accession number E-MTAB-6073, entitled "Transcriptomic differences in livers of mice fed with normal diet and choline-deficient high-fat diet". Raw sequencing data for the fat tissue is available under the accession number MTAB-7625.
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Field-specific reporting Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
Pilot experiments and previous published results were used to estimate the sample size such that appropriate statistical tests could yield significant results. The exact n numbers used in the study are indicated in the respective Figure Legends .
Data exclusions Exclusion criteria was pre-established and the CD-HFD fed mice which did not show the NASH phenotype, high ALT, AST and body weight,
were excluded from the analysis.
Replication
All experiments presented were conducted with sufficient mouse numbers to ensure statistical significance could be reached, particularly for experiments involving tumor studies. In addition, many of the experiments, including (APT) were conducted in multiple cohorts in different animal husbandries (Zurich, Heidelberg). Biochemical or image based data were reproduced in multiple mice: e.g. Weight analysis of mice, Measuring transaminase levels, lipid levels (liver triglycerides, LDL, vLDL etc.) NASH phenotype characterization, HCC development characterization, FACS analyses, sudan red quantification, platelet counting, qRT-PCR, confocal analysis, MRI analysis etc.
Randomization 5-week-old C57Bl/6 mice were randomly allocated into different groups and were fed with appropriated diet or treatment regimens.
For patients involved into the clinical study blinding was used. E.g several analyses performed by radiologists were blinded, as were serum analyses.
Blinding
Experiments with different genotypes on the same diet were blinded. For the dissection between ND or CD-HFD mouse experiments this was not possible since the type of diet was visible to the researcher, e.g., the color of the normal diet is brown and color of the CD-HFD is green. The analysis of the transaminase level was blinded and measured with code labeling. The characterization of the tumour was blinded to the pathologist. The NASH phenotype analysis was blinded -still the morphology of the normal liver is different from a NASH liver.
Reporting for specific materials, systems and methods To investigate the effects of APT on human NAFLD, we started an initial prospective clinical trial (German Clinical Trials Register (DRKS) 587/2016BO2) with NAFLD patients (BMI>30; obesity, arterial hypertension, hyperlipidemia, diabetes mellitus type 2, constantly increased LDL, vLDL and serum cholesterol levels) undergoing a heart catheter procedure and subsequent APT for 6 months.
To decrease potential biases (assignment of patients according to ethical and clinical care guidelines), we performed the a multivariate analysis (age, gender, antiaggregation and new statin treatment).
Flow Cytometry Plots
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The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
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Methodology Sample preparation
Please see Supplementary Materials.
The primary method: perfusion with HBSS of livers, cut the liver mechanically into small pieces. After Collagenase IV+DNAse I digestion, cells were purified by a 2 step Percoll/HBSS gradient (25%/50%).
The secondary method: livers were perfused once with PBS followed by collagenase digestion at 37°C for 40 minutes (collagenase type IV, Worthington, UK). Additionally, 0.1 mg/ml DNase I was added after 20 min. Single cell suspension was obtained by filtering the digested liver through a 70 μm mesh. Hepatocytes were removed by low speed centrifugation (50 rcf, 1 min) and density gradient centrifugation was performed using 18 % Nycodenz dissolved in Gey`s Balanced Salt Solution (GBSS) as previously described
Instrument
Sony Spectral Analyzer SP6800 and BD LSRFortessa Cell Analyzer Software SP6800 V1.6.3.7151 or FACS Diva Version 8.0.1 for data collection and FlowJo V10.2 for analysis.
Analysis was also done using FlowLogic (v7.2, Inivai, Australia) and FlowJo (v10.4, BD Biosciences)
Cell population abundance Absolute quantification by using CountBright™ Absolute Counting Beads.
Gating strategy
Debry esclusion byFSC-A/SSC-A. Doublets were excluded by using FSC-A/ FSC-H and SSC-A/SSC-H gates. Life/Dead exclusion was performed by ZombieDye NIR staining. Cells negative for ZombieDye NIR were further characterized: T-cells: Gated for CD8 and CD4. CD8+ cells were further characterized by CD62L-negativity and CD8+CD62L-cells were gated to CD44 and CD69. NKT cells: Cells negative for ZombieDyeNIR were gated to NK1.1+ and CD335+. NK1.1+CD335+ cells were further characterized by CD3+ (NKT cells) and CD3-(NK cells). NK1.1+CD335+CD3+ cells were characterized by a-Gal positivity.
All other stainings are provided in the Supplemental Material.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
